Home » ARYx Sees Successful Drug Cardiac Safety Results
ARYx Sees Successful Drug Cardiac Safety Results
ARYx Therapeutics reported positive results of Thorough QT, a cardiac safety study for its prokinetic agent ATI-7505 conducted in conjunction with Procter & Gamble.
The agent is in Phase II clinical trials for chronic constipation and functional dyspepsia.
Results showed that electrocardiographic effects at therapeutic and supra-therapeutic doses were negative, ARYx said.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May